Your Wellness Device Is Smarter Than Ever. Is It Still a “Wellness” Product?

The latest generation of wellness technology is doing much more than counting steps.

Today’s wearables can estimate blood pressure trends, analyze heart rate variability, monitor oxygen saturation, evaluate sleep quality, assess recovery, and use sophisticated algorithms to provide users with personalized insights.

In short: your smartwatch may know you need a nap before you do.

As wellness technologies become more sophisticated, however, companies face an increasingly important regulatory question:

When does a wellness product remain a wellness product—and when does it become an FDA-regulated medical device?

FDA revised its General Wellness: Policy for Low Risk Devices guidance this year, replacing its 2019 guidance and providing updated clarity on the Agency’s approach to modern digital health technologies, including non-invasive wearable products and software functions. The revised guidance reflects FDA’s effort to encourage innovation while maintaining clear boundaries between general wellness products and medical devices subject to FDA oversight.

The Two Questions Every Wellness Company Must Ask

Under FDA’s general wellness framework, the analysis generally focuses on two key questions:

1. Is the Product Intended Solely for General Wellness Use?

FDA continues to recognize two categories of permissible general wellness intended uses:

Category 1: General health and healthy lifestyle claims

Examples include claims related to:

• Maintaining a healthy weight;
• Improving physical fitness;
• Promoting relaxation or stress management;
• Supporting sleep quality;
• Encouraging healthy eating habits.

Category 2: Lifestyle claims associated with reducing the risk or impact of certain chronic diseases or conditions

These claims are permissible only where it is well understood that healthy lifestyle choices may help reduce the risk or help individuals live well with certain chronic diseases or conditions.

For example, a product that promotes exercise to help maintain cardiovascular health may fall within the policy.

The key is that the product must not be intended to diagnose, cure, mitigate, prevent, or treat a disease or condition. Once a company crosses into clinical claims, FDA’s regulatory interest generally increases.

The Biggest Change: More Flexibility for Modern Wearables

Perhaps the most significant aspect of FDA’s revised guidance is its recognition that modern wellness products may measure or estimate physiological parameters that historically have been associated with clinical use.

This is a meaningful development for innovators developing next-generation wearables and AI-enabled wellness tools.

In other words, measuring a health metric does not automatically make your product a medical device.

But—and there is always a regulatory “but”—how you describe that measurement may determine whether FDA views your product differently.

Your Marketing Team May Determine Your Regulatory Pathway

A device that estimates blood glucose trends to help users understand how food choices impact their wellness may potentially fit within FDA’s policy, provided it meets the conditions of the guidance.

The same technology marketed as detecting diabetes, preventing diabetic complications, or replacing a clinical glucose monitor may trigger medical device requirements.

The difference may be only a few words.

Those words may also be worth millions of dollars in regulatory obligations.

Companies should evaluate:

• Product labels and packaging;
• Website content;
• Mobile applications and user interfaces;
• AI-generated outputs and recommendations;
• Advertising and social media claims;
• Influencer and affiliate statements;
• User instructions and disclaimers.

The Low-Risk Requirement Still Matters

Even if a product has a wellness-related intended use, it must also present a low risk to the safety of users and others.

FDA’s policy generally does not apply to invasive products. For example, FDA specifically explained that a wearable using minimally invasive microneedle technology to estimate blood glucose would not be considered low risk under the general wellness policy—even if the intended use is framed as wellness-related.

Similarly, products that are intended to substitute for FDA-authorized medical devices, direct clinical decisions, or provide diagnostic information may fall outside the policy.

What Should Innovative Device Companies Do Now?

Companies developing next-generation wellness products should carefully evaluate whether their products fit within the boundaries of FDA’s general wellness policy, including whether their intended use, claims, functionality, and overall product strategy align with FDA’s expectations.

The cost of getting this analysis wrong may extend beyond regulatory uncertainty. A product that unexpectedly falls within FDA’s medical device framework may face additional regulatory obligations, delayed commercialization, increased costs, and investor concerns.

The companies that will succeed in the future of digital health will not necessarily be those with the most sophisticated sensors or the most advanced algorithms.

They will be the companies that understand how to build innovation with a regulatory strategy from the beginning.

The smartest companies do not ask, “How close can we get to the medical device line without crossing it?”

They ask a more valuable question:

“How do we design a product, claim strategy, and regulatory roadmap that supports growth without creating unnecessary regulatory risk?”

The future of digital health will not be built solely by the companies with the most sophisticated sensors or the most advanced algorithms.

It will be built by the companies that understand how innovation and regulation work together.

For more information and support with FDA’s general wellness policy, medical device/ product classification, compliant claims strategies, and regulatory pathways that support innovation and commercialization, please contact info@garg-law.com.